PTK2 and breast carcinoma: Interestingly, α-mangostin (1–4 μM/24 h) disrupts FAK activation by blocking Tyr397 phosphorylation at the active site, thereby reducing its interaction with extracellular matrix-associated proteins in MCF-7 and MDA-MB-231 breast cancer cells.